drugset / Trial / NCT00642928
Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
The objective of this trial is to define the minimum effective dose of BF 2.649 between 5 mg, 10 mg, 20 mg or 40 mg versus placebo in reducing the Excessive Daytime Sleepiness of Parkinson's disease patients
Timeline
- Start
- 2007-10
- Primary completion
- 2009-03
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pitolisant | Small molecule | 5 mg | Oral |
| Subject | Pitolisant | Small molecule | 10 mg | Oral |
| Subject | Pitolisant | Small molecule | 20 mg | Oral |
| Subject | Pitolisant | Small molecule | 40 mg | Oral |